HCV Viral knetics among HIV co-infected patients / "Estudo da cinética viral do vírus da hepatite C em pacientes co-infecatados com o HIV"

AUTOR(ES)

Evaldo Stanislau Affonso de Araújo

DATA DE PUBLICAÇÃO

2006

RESUMO

Twenty six co-infected patients were treated with PegIFN A2A and Ribavirin for 48 weeks. Twenty samples were drew at hours 0, 4, 8, 12, 18, 24, 30, 36, 42, 48, days 3, 4, 7, 8, 22, 29, 43, 57 and week 12 to HIV and HCV (TaqMan®) quantification after began medication. Basal data showed Genotype 1 in 15 patients, 3 in 11. Median HCV were 1.285.000 UI/ml, mean CD4 573/mm3 and mean HIV 1109 cp/ml. SVR was associated only with Genotype 3 (p<0,04). Overal SVR (ITT) were 26,9%. We obtained fitted viral kinetics parameters for 18 patients. Patients with SVR showed higher Interferon efficacy, infected cells clearance, free virion clearance and faster phase 1 and 2. Reduction on HCV load of less than one log10 at 24 or 48 hs had a NPV of 100% for SVR. Less than two log decay at days 8 and 29 had 92,31 and 100% of NPV and the presence of those reduction were associated with SVR p=0,003 and p=0,01). Viral kinetics are an important tool regarding clinic management and very early prediction of absence of SVR, wich is very important for the HIV co-infected patients for whom the clicical management is very complex.

ASSUNTO(S)

interferon alfa-2a interferon alpha-2a hepatitis c kinetics cinética hiv hepatite c hiv

Documentos Relacionados

• Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
• Clinical and epidemiological features of patients with chronic hepatitis C co-infected with HIV
• Viral acute gastroenteritis: clinical and epidemiological features of co-infected patients
• Hepatitis C viral load in HCV-monoinfected and HCV/HIV-1-, HCV/HTLV-1/-2-, and HCV/HIV/HTLV-1/-2-co-infected patients from São Paulo, Brazil
• There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV